Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Holding ZLAB?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.69Last Year’s EPS
-1.63Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 07, 2019
|% Change Since: -15.50%
|Next Earnings Date:Aug 30, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the successful launch of VYVGART, significant advancements in the pipeline, and a substantial reduction in net loss. While there were some increased R&D expenses, the overall financial health and strategic progress indicate a positive outlook.Company Guidance
During Zai Lab's Q3 2024 earnings call, the company provided detailed guidance, highlighting significant advancements and projections across its portfolio. Total net product revenue saw a robust 47% year-over-year increase, reaching $101.8 million, driven notably by the successful launch of VYVGART, which alone contributed $27.3 million. The company anticipates VYVGART sales to exceed $80 million for the year. Furthermore, Zai Lab is optimistic about achieving profitability by the end of 2025, with a current cash position of $716 million. The firm also emphasized the potential for VYVGART to surpass $1 billion in annual sales in China, bolstered by the approval of its subcutaneous formulation for CIDP. In terms of pipeline growth, Zai Lab is advancing several promising candidates, including ZL-1310 for small cell lung cancer, which demonstrated a 74% objective response rate in early trials, and is preparing for the launch of KarXT in schizophrenia, positioning it as a potential blockbuster. Additionally, the company reported a 40% improvement in net loss for the quarter compared to the previous year, reflecting enhanced operational efficiency.Strong Revenue Growth
Total net product revenue for the third quarter grew 47% year-over-year to $101.8 million, led by the launch of VYVGART, and supported by sales for ZEJULA and NUZYRA.
VYVGART Performance
VYVGART's launch in gMG in China is exceptionally strong, with sales on track to exceed $80 million for the year. Approximately 10,000 patients have been treated, with a significant increase in repeat patients.
Pipeline Advancements
Significant progress in the global pipeline including ZL-1310 with a 74% objective response rate in small cell lung cancer and the approval of VYVGART Hytrulo for CIDP.
Reduction in Net Loss
Achieved a 40% improvement in net loss in the third quarter compared to the previous year, with a focus on achieving profitability by the end of 2025.
Strategic Pipeline Progress
Late-stage pipeline progressing with potential approvals for KarXT in schizophrenia and Bemarituzumab in gastric cancer, targeting substantial market opportunities.
---
ZLAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZLAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $31.09 | $28.96 | -6.85% |
| Aug 06, 2024 | $18.11 | $16.65 | -8.06% |
| May 08, 2024 | $16.57 | $21.01 | +26.80% |
| Feb 27, 2024 | $22.49 | $20.80 | -7.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zai Lab (ZLAB) report earnings?
Zai Lab (ZLAB) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Zai Lab (ZLAB) earnings time?
Zai Lab (ZLAB) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLAB EPS forecast?
ZLAB EPS forecast for the fiscal quarter 2024 (Q4) is -0.69.
---